

## INDEX

- acceding countries, 25
- Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). *See also* unfair competition
  - abuse of intellectual property rights, 143
  - anti-competitive licensing practices, 144
  - compulsory licensing, 144
  - IP and competition policy current issues, 144
- anti-competitive practices. *See* unfair competition
- appellations of origin, 90
- Australia – Tobacco Plain Packaging*, 66, 77–80, 195
- beneficiaries, 15–17, 34
- Berne Convention, 12, 34
  - beneficiaries, 16
  - copyright. *See* copyright and related rights
  - enforcement. *See* enforcement
  - exceptions to national treatment and MFN treatment, 17
  - moral rights, 12, 40, 49
  - rule of retroactivity, 26
  - and TRIPS Agreement, 12, 16, 40–2
  - TRIPS Agreement as ‘Berne-plus’, 40
- biodiversity, 216, 226–31. *See also* traditional knowledge and folklore
- biotechnology patenting, 113, 216, 227
- border measures, 157–62
  - procedural requirements and safeguards against abuse, 159–61
- application, including evidence and description of goods, 159
  - duration of suspension, 160
  - notice of suspension, 160
  - posting of security/payment of compensation, 160
- remedies and orders for destruction/disposal, 161–2
- right of inspection and information, 161
- scope and coverage, 157–9
  - mandatory coverage of pirated copyright/counterfeit trademark goods, 157–8
  - optional coverage, 158–9
  - special rules for *ex officio* action, 162
  - suspension of release, 14, 157
- broadcasting organizations, related rights, 17, 18. *See also* related rights
- Canada – Pharmaceutical Patents*, 117, 119–20, 178
- Canada – Term of Patent Protection*, 25, 178
- certification marks, 63, 86, 91
- China – Intellectual Property Rights*, 162, 164, 195
- climate change, current TRIPS issues, 237–8
- collective management organizations, 48
- collective marks and certification marks, 63, 86, 91, 94
- competition law and policy. *See* unfair competition

- 'competition law and policy,' meaning of, 142
- compulsory licences
- developing countries/LDCs
    - educational purposes, 51
    - medicines. *See* TRIPS and public health
  - emergency situations, 122, 201
  - grounds when normal requirements for compulsory licensing do not apply, 122, 201
  - layout-designs of integrated circuits, 135
  - meaning of, 121
  - medicines and pharmaceuticals. *See* TRIPS and public health
  - no compulsory licensing of trademarks permitted, 81–4
  - patents, 116–17, 121–4
    - applications to be considered on individual merits, 122
    - conditions to be met in case of dependent patents, 123
    - conditions to be respected in the grant of compulsory licences, 121–4
    - decisions on grant/remuneration subject to judicial/independent review, 123
    - licences predominantly for supply of domestic market, 122, 144, 204, 206
    - licences to be non-exclusive, 122
    - remedying anti-competitive practices, 122, 144
    - right holder, adequate remuneration for, 123, 144, 204, 206
    - scope and duration to be limited to purposes for which granted, 122
    - unsuccessful attempt first to obtain a voluntary licence, 122
  - pharmaceutical exports. *See* Paragraph 6 System
  - semi-conductor technology, 135
  - computer programs, 42, 47, 54, 55
  - confidential information. *See* undisclosed information
- Convention on Biological Diversity (CBD), 114
- and TRIPS Agreement and protecting traditional knowledge/folklore, 114, 216, 220, 229–31, 232
  - current issues, 216, 220, 229–32
- copyright and related rights, 2, 39–57
- authors' general rights, 46–7
  - beneficiaries, 16
  - Berne Convention and copyright, 39, 40
  - copyright including related or 'neighbouring rights', 40
  - copyright or 'authors' rights', 39
  - definition of, 39–40
  - limitations and exceptions to
    - exclusive rights of authors, 49–53
    - fair use or fair dealing, 50
    - free use, 50
    - minor exceptions, 50
    - non-voluntary licences, 50, 51
    - three-step test, 51
  - pre-existing works and phonograms, 26
  - principles governing eligibility for copyright protection, 44–6
    - automatic protection, 45
    - idea/expression dichotomy, 44
    - independence of protection, 46
    - originality, 45
  - purpose of protection of copyright and related rights, 3, 40
  - related rights. *See* related rights
  - relationship of TRIPS Agreement with Berne and Rome Conventions, 40–2
  - rights to be conferred on
    - authors, 46–9
    - authors' general rights, 46–7
    - economic rights, 46
    - moral rights, 12, 40, 46, 49
    - rental right, 47
    - reproduction right, 47
    - rights of public performance, broadcasting and communication to public, 48

- copyright and related rights (cont.)  
 rights of translation and  
 adaptation, 49  
 subject matter to be protected, 42–6  
 certain other categories of  
 works, 44  
 derivative works, 43  
 literary and artistic works. *See*  
 literary and artistic works  
 principles governing eligibility for  
 copyright protection, 44–6  
 translations and adaptations, 43, 49  
 TRIPS provisions on copyright,  
 42–54  
 minimum term of  
 protection, 53–4  
 permissible limitations and  
 exceptions, 49–53  
 rights to be conferred on  
 authors, 46–9  
 subject matter to be  
 protected, 42–6  
 Copyright Treaty, WIPO, 41, 236  
 counterfeiting, copying and piracy. *See*  
*also* enforcement  
 border measures, 157–8  
 concerns about counterfeiting and  
 piracy, 146  
 copyright piracy, 54, 146, 148, 155,  
 157–8, 162  
 definition of, 158  
 counterfeiting, 128, 146  
 international trade in, 148  
 trademark counterfeiting, 148, 154,  
 155, 157–8, 161, 162  
 definition of, 157  
 criminal procedures and penalties, 164.  
*See also* enforcement  
 remedies, 164  
 scope and coverage, 162  
 current TRIPS issues, 32, 35, 216–53  
 climate change, 237–8  
 competition policy, 240–1  
 current issues, 216, 221–37  
 electronic commerce, 217, 236–7  
 geographical indications, 216,  
 221–6  
 LDCs, 217, 233–5  
 non-violation complaints,  
 217, 232  
 transfer of technology, 217,  
 235–6  
 the ‘triplets’: biotech, traditional  
 knowledge and biodiversity,  
 216, 226–31  
 geographical indications, 216,  
 221–6  
 background, 221–2  
 higher-level protection for non-  
 wine/spirits products, 218–21,  
 222, 225–6  
 notification/registration system  
 for GIs for wines/spirits, 218,  
 221, 222–5  
 innovation, support for, 238–9  
 mandates for work on the TRIPS  
 issues, 218–21  
 bases for ongoing work, 218  
 debate over nature of mandates,  
 220, 225  
 whether issues should be linked or  
 handled separately, 220  
 non-violation complaints, 217, 232  
 TRIPS Council examining scope  
 and modalities, 217  
 transfer of technology, 235–6  
 the ‘triplets’: biotech, traditional  
 knowledge and biodiversity,  
 216, 226–31  
 Article 27.3(b) review, 227–8  
 relationship between the TRIPS  
 Agreement and the CBD, 229–31  
 traditional knowledge and  
 folklore, 229–31  
 TRIPS Agreement in other  
 multilateral policy processes,  
 242–53  
 debates on issues outside the  
 WTO, 216–18  
 development issues, 248–50  
 environmental agreements, 251–3  
 human rights, 242–4  
 IP and competition policy, 144,  
 250–1  
 public health beyond the WTO,  
 244–8

- databases, 43
- Denmark and Sweden – Measures Affecting the Enforcement of IPRs*, 195
- derivative works, 43
- developed countries
  - assisting developing countries
    - current issues, 235–6
    - monitoring obligations on technology transfer, 235
    - technical cooperation, 27–8, 217, 234
  - assisting LDCs, 24
    - technical cooperation, 27–8, 234
    - technology transfer, 26–7, 203, 217, 233
  - transition periods, 23
- developing countries
  - assistance and technical cooperation
    - from developed countries, 27–8, 217, 234
  - assistance from WIPO/WTO
    - technical cooperation and assistance, 37
    - translation of laws/regulations, 36
  - compulsory licensing, medicines
    - educational purposes, 51
    - medicines. *See* TRIPS and public health
  - copyright, 41
  - current TRIPS issues on
    - development, 248–50
  - Paragraph 6 System. *See also* Paragraph 6 System
    - generic producers, 204, 212
    - re-exporting pharmaceutical products and regional trade agreements, 212
    - review of System's functioning, 214
  - textile design protection, 128
  - transition periods, 23–4
  - TRIPS negotiations, 7
    - outstanding implementation issues, 218
  - dispute prevention and settlement, 13, 166–97
    - clarifications of TRIPS Agreement in dispute settlement, 30
    - description of dispute settlement procedures, 173–7
      - adoption of Panel/Appellate report(s) and implementation, 175–7
      - Appellate review, 175
      - consultations between the parties, 173
      - Panel examination, 174–5
      - retaliation and cross-retaliation, 176
    - dispute prevention and review of national implementing legislation. *See also* TRIPS Council
    - dispute settlement, 168–73
      - general overview of system, 168–71
      - grounds for complaints, 170
      - member governments initiating dispute settlement procedures, 168, 169
      - non-violation and situation complaints, 171–3
      - private parties, 169
      - and review of national implementing legislation, 167–8
      - third parties, 169, 173
      - violation complaints, 170
    - Dispute Settlement Body (DSB), 170, 174, 176
    - DSU, 10, 169
    - exhaustion of IPRs, 21, 202
    - general statements, 200
    - guide to resources, 195–7
    - non-violation and situation complaints, 171–3
      - current issues, 217, 232
      - moratorium on application of complaints, 8, 170, 172
      - TRIPS Council examining scope and modalities, 172, 217
    - and objectives/principles of TRIPS Agreement, 14
    - as TRIPS Agreement key feature, 166
    - TRIPS-related cases, 177–97

- distinctive signs, 61–3. *See also*  
 geographical indications (GIs);  
 trademarks
- Doha Declaration on the TRIPS  
 Agreement and Public Health,  
 21, 35, 198, 216, 236
- clarification of flexibilities, 201–2
- compulsory licences, 121, 122, 201
- concerns that triggered discussions,  
 199–200
- emergency situations, 122, 201
- follow-up, 203
- general statements, 200–1
- interpreting TRIPS Agreement, 14
- LDCs and pharmaceutical product  
 patents, 24, 233
- scope of application, 200
- transfer of technology, 203
- Doha Development Agenda, 10, 218
- Doha Ministerial Declaration, 21, 32,  
 35, 100, 114
- current TRIPS issues, 218–21,  
 222, 226
- EC – Bananas III*, 177
- EC – Trademarks and Geographical  
 Indications*, 81–3, 178
- electronic commerce, 217, 236–7
- complexity of IP issues, 236
- no customs duties on electronic  
 transmissions, 236
- TRIPS Council, 237
- enforcement, 13, 146–65
- application of basic principles, 148
- background, 146
- border measures. *See* border  
 measures
- civil and administrative procedures  
 and remedies, 151–5
- evidence, 151, 152, 155, 159
- fair and equitable procedures,  
 150, 151
- cooperation and contact points
- contact points, 165
- cooperation between  
 members, 165
- current issues, 217
- decisions on merits of case, 151
- effects of infringement, 147
- general obligations, 149–51
- basic principles of due  
 process, 151
- indemnification of defendant, 154–5,  
 156, 160
- IPR enforcement described, 147–8
- relationship of TRIPS Agreement  
 with other pre-existing treaty  
 provisions, 146, 149
- remedies, 152–4
- damages, 153–4
- injunctions, 153, 155
- other remedies and orders for  
 destruction/removal, 154
- right of appeal, 151
- right of information, 154
- environmental agreements, 251–3
- EU trademarks, 72–4
- European Communities and Portugal –  
 Enforcement of IPRs in Motion  
 Pictures and Television  
 Programs*, 195
- exclusive rights, 1, 178
- developing countries/economies in  
 transition and exclusive  
 marketing rights, 24
- LDCs and marketing rights, 24,  
 31, 203
- exhaustion, 20
- international exhaustion regimes,  
 20, 202
- layout-designs of integrated  
 circuits, 135
- meaning of, 20
- national exhaustion regimes, 20, 202
- and parallel importation, 20
- regional exhaustion regimes, 21
- free riding. *See* unfair competition
- General Agreement on Tariffs and  
 Trade (GATT)
- GATT (1947), 4, 5
- GATT (1994), 5, 167, 169
- Tokyo Round, 6, 146
- Uruguay Round, 5, 218
- counterfeit goods, 146, 148

- TRIPS negotiations, 14, 21, 40, 60, 85, 98
- general provisions and basic principles of TRIPS Agreement, 14
- beneficiaries, 15–17
- exhaustion. *See* exhaustion
- minimum standards agreement, 15
- national/MFN treatment. *See* national treatment and MFN treatment
- objectives and principles, 14
- generic producers, 204, 212
- geographical indications (GIs), 2, 85–104
  - additional protection for GIs for wines and spirits (Article 23), 98–101
  - homonymous GIs for wines (Article 23.3), 100
  - negotiation of a multilateral register of GIs for wines (Article 23.4), 100
  - protection against use as a trademark (Article 23.2), 100
  - protection against use by others (Article 23.1), 99
  - background, 85–6
  - collective marks, 63, 91, 94
  - current issues, 216, 221–6
    - background, 221–2
    - higher-level protection for products other than wine/spirits, 218, 225–6
    - notification/registration system for GIs for wines/spirits, 218, 221, 222–5
  - definition of, 85, 87
  - elements of Article 22.1 definition 78–80
    - function of identification, 88
    - geographical origin identified by GI, 88
    - quality, reputation or other characteristics due to geographical origin, 89
    - subject matter of identification, 88
  - exceptions, 101–4
    - generic terms (Article 24.6), 101
    - GIs not protected in country of origin/fallen into disuse (Article 24.9), 103
    - prior trademark rights (Article 24.5), 102
    - prior use of GI (Article 24.4), 102
    - time limit to challenge trademarks under Articles 22.3 and 23.2 (Article 24.7), 103
    - use by a person of his name (Article 24.8), 103
- GIs, indications of source, rules and appellations of origin, trademarks
  - geographical indications and appellations of origin, 90
  - geographical indications and indications of source, 90
  - geographical indications and rules of origin, 90
  - geographical indications, trademarks and certification marks, 91
  - indefinite protection, 2
  - indications of source, rules and appellations of origin, trademarks, 89–94
  - international negotiations, review and standstill, 104
    - international negotiations (Article 24.1), 104
    - standstill (Article 24.3), 104
  - notification/registration system for GIs for wines/spirits, 218, 221, 222–5
  - and Paris Convention, 85, 86
    - relationship of TRIPS Agreement with pre-existing provisions, 86
  - protection and rights conferred for geographical indications for all goods, 95–101
    - factually true but misleading use (Article 22.4), 98
    - protection against use by others (Article 22.2), 95–7
    - protection against uses as a trademark (Article 22.3), 97
  - purposes of GI protection, 4

- geographical indications (GIs) (cont.)  
 subject matter to be protected 78–84  
 definition of, 85  
 definition of GIs, 87  
 elements of Article 22.1  
 definition, 87–9  
 examples of GIs and logos or symbols, 92–4  
 indications of source, rules and appellations of origin, trademarks, 89–94  
 right holders and eligible users, 91  
 trademarks, 70  
 TRIPS provisions on geographical indications, 87–104  
 conditions for getting protection, 94  
 subject matter to be protected, 87–91
- Handbook on the WTO Dispute Settlement System* (WTO Secretariat), 196
- health  
 public health. *See* TRIPS Agreement and public health
- historical and legal background to TRIPS, 4–8  
 TRIPS negotiations, 6–8
- human rights and the TRIPS Agreement, 242–4
- India – Patents I and II*, 24, 178
- indigenous peoples  
 traditional knowledge and folklore.  
*See* traditional knowledge and folklore
- industrial designs, 2, 44, 126–30  
 definition of, 127  
 general formalities for protection, 128  
 general formalities for protection of industrial designs formalities, 128  
 priority, 128  
 minimum term of protection, 130  
 permitted exceptions to rights conferred, 130  
 rights to be conferred, 129–30  
 rights to be conferred on owners of a protected industrial design, protection not including forfeiture, 129  
 subject matter to be protected, 127–9  
 general formalities for protection, 128  
 protection for new or original designs and independently created designs, 127  
 textile designs, 128–9
- industrial property, 2, 44  
 beneficiaries, 15  
 distinctive signs. *See* geographical indications (GIs); trademarks  
 inventions/new technologies. *See* industrial designs; patents
- innovation  
 current issues in support for, 238–9  
 recognizing and stimulating, 3, 14, 106
- institutional arrangements, 13, 28–38  
 Council for TRIPS. *See* TRIPS Council  
 WTO Agreement. *See* World Trade Organization (WTO)
- integrated circuits. *See* layout-designs (topographies) of integrated circuits
- intellectual property (IP) system  
 intellectual property rights. *See* intellectual property rights (IPRs)  
 public policy tool, 3–4
- Intellectual Property in Respect of Integrated Circuits (IPIC) Treaty, 12, 22, 131  
 beneficiaries, 15  
 layout-designs. *See* layout-designs (topographies) of integrated circuits  
 national treatment and MFN treatment, 17, 18
- intellectual property rights (IPRs), 1–3  
 acquisition and maintenance of IPRs, 13, 22

- copyright. *See* copyright and related rights  
 current TRIPS issues as to  
   competition policy, 250–1  
 enforcement. *See* enforcement  
 exclusive rights. *See* exclusive rights  
 industrial property. *See* industrial property  
 nature of, 1  
 and public interest, 240  
 standards for availability, scope and use of, 11–12  
 territorial rights, 2, 60  
 International Union for the Protection of New Plant Varieties (UPOV Convention), 113  
 Internet, 236  
   WIPO Internet treaties, 41  
  
*Japan – Measures Concerning Sound Recordings*, 26, 178  
  
 layout-designs (topographies) of  
   integrated circuits, 131–5  
 definition of, 131–2  
 limitations and exceptions to rights conferred, 133–5  
   compulsory licensing, 135  
   exhaustion, 135  
   innocent infringement, 134  
   parallel creation, 134  
   reproduction for private or research purposes, 133  
 minimum term of protection, 135  
 rights to be conferred, 133  
 subject matter to be protected, 132–3  
   originality and not commonplace requirements, 132  
 least-developed countries (LDCs). *See also* developing countries  
   assistance and technical cooperation  
     Joint Initiative on Technical Cooperation for Least-Developed Countries, 234  
     Swedish International Development Cooperation Agency report (2013), 234  
   from WIPO/WTO, 37, 234  
  
   assistance and technology transfer  
     from developed countries, 24  
     technical cooperation, 27–8, 234  
     technology transfer, 26–7, 203, 217, 233, 235–6  
 compulsory licensing, current TRIPS issues, 233–5  
 helping LDCs to implement TRIPS, 234  
 Paragraph 6 System, 208  
   deemed insufficient or no manufacturing capacity, 209  
   re-exporting and regional trade agreements, 212  
 transition periods, 24–5, 233  
   extension for pharmaceutical products, 31, 203, 233  
   waiver of obligations concerning exclusive marketing rights, 24, 31, 203  
 licences. *See* anti-competitive practices in contractual licences, control of; compulsory licences  
 literary and artistic works, 42–3  
   computer programs, 42  
   databases, 43  
  
 Madrid Agreement and Madrid Protocol, 19, 94  
 Marrakesh Agreement, 5, 8, 55, 169  
 medicines and pharmaceutical products. *See* TRIPS and public health  
 MFN treatment. *See* national treatment and MFN treatment  
 minimum standards agreement, 15  
 moral rights, 12, 40, 49  
 Multilateral Trade Organization, 8  
  
 national law, 15, 32  
   anti-competitive practices, 142  
   competition law and policy. *See* competition law and policy  
   copyright, 39, 44  
   limitations and exceptions. *See* copyright and related rights



- national law (cont.)  
 differences in national legal systems  
 to be taken into account,  
 147, 148  
 enforcement, 147, 148  
 GIs, 86, 88, 94, 96, 98, 104  
 industrial designs, 127, 129  
 layout-designs of integrated  
 circuits, 132  
 monitoring of members' compliance  
 with obligations. *See* TRIPS  
 Council  
 notifications. *See* notifications  
 official texts, 44  
 patents, 105, 111, 113, 226  
 public health, 198, 200, 201, 205,  
 213  
 publication of laws, regulations and  
 judicial decisions, 167  
 related rights, 55  
 review of national laws and  
 regulations. *See* TRIPS Council  
 supply of information on laws and  
 judicial decisions to other  
 Members, 168  
 trademarks, 58, 63, 64, 66, 71,  
 76  
 permissible exceptions. *See*  
 trademarks  
 national treatment and MFN  
 treatment, 17–19, 21, 23  
 enforcement procedures and  
 remedies, 148  
 exceptions, 17, 18–19  
 GIs, 85  
 MFN, 17, 18–19, 34  
 national treatment, 17–19, 34  
 exceptions nationality, 15, 16  
 non-discrimination. *See* national  
 treatment and MFN treatment  
 non-violation. *See* dispute prevention  
 and settlement  
 notifications, 33–4, 167  
 cooperation between WTO and  
 WIPO, 36–8  
 Paragraph 6 System, 209–10  
 review of national laws and  
 regulations, 35  
 objectives and principles of TRIPS  
 Agreement, 14  
*ordre public*. *See* security interests  
*Pakistan – Patent Protection for  
 Pharmaceutical and  
 Agricultural Chemical  
 Products*, 178  
 Paragraph 6 System, 204–15  
 Chairman's statement, 212–13  
 description of, 205–12  
 avoidance of double  
 remuneration, 211  
 eligible importing members, 208  
 exporting members, 209  
 notifications, 209–10  
 regional trade agreements as  
 special cases, 211–12  
 safeguards against diversion,  
 210–11  
 scope and coverage, 208  
 establishment of, 203, 204–5  
 legal basis of, 206  
 national implementing  
 legislation, 213  
 in a nutshell, 207–8  
 reason for, 204  
 review of functioning of, 214–15  
 use of, 214  
 parallel imports, 20, 158, 202  
 Paris Convention, 12, 22, 40  
 beneficiaries, 15  
 enforcement, 146  
 GIs. *See* geographical  
 indications (GIs)  
 national emblem protection, 37, 70  
 national treatment and MFN, 17  
 patents. *See* patents  
 trademarks. *See* trademarks  
 and TRIPS Agreement, 12, 15, 60,  
 86, 106  
 unfair competition, 136  
 patents, 2, 105–25. *See also* industrial  
 designs  
 conditions inventions must meet to  
 be eligible for patent protection,  
 108–14  
 'best mode' requirement, 110

- formal conditions, 105, 108, 111
- non-discrimination, 111, 116–17, 120
- novelty, inventive step and industrial applicability, 108–10
- permissible exclusions from patentable subject matter, 111–13
- priority, 110
- relationship between TRIPS Agreement/CBD/traditional knowledge, 114
- review of Article 27.3(b), 113, 226
- substantive conditions, 108
- current issues, 216, 226–31
  - Article 27.3(b) review, 227–8
  - relationship between TRIPS Agreement and CBD, 229–31
  - traditional knowledge and folklore, 228–9
- definition of, 105–6
- dependent patents, 123
- developing countries and transitional arrangements, 23–4
- exceptions that WTO members can allow to patent rights, 117–24
  - compulsory licences
    - See compulsory licences
    - limited exceptions, 118–20
- fees, 124
- ‘invention,’ definition of, 105
- LDCs and transitional arrangements, 24–5, 203
- medicines and pharmaceutical products. *See* TRIPS and public health
- minimum period of protection to be accorded, 124
  - term of protection, 2, 124
- novelty, inventive step and industrial applicability, 108–10
  - industrial applicability/utility, 109, 112
  - inventive step/non-obviousness, 109
  - novelty, 108
- permissible exclusions from patentable subject matter, 111–13
  - methods of treatment, 112
  - ordre public* or morality, 112
  - plants and animals, 113, 226
- prior art, 23, 108, 109, 110
- process patents, rights to be conferred on owners of, 115–16
  - burden of proof, 115–16
  - rights of process patent owners, 115–16
- purposes of patent protection, 4, 14, 106, 110
- relationship of TRIPS Agreement with Paris Convention pre-existing provisions, 106
- revocation, 125–5
- rights to be conferred on patent owners, 114–17
  - assignment, transfer and licensing of patents, 117
  - non-discrimination with respect to availability and enjoyment of patent rights, 111, 116–17, 120
  - other rights of patent owners, 117
  - rights to be conferred on owners of process patents, 115–16
  - rights to be conferred on owners of product patents, 115
- subject matter to be protected by patents, 107–14
  - areas in which inventions must be eligible for protection, 107
  - conditions inventions must meet to be eligible for patent protection, 108–14
- three-step test, 118
- traditional knowledge and folklore, 114, 228–9
- TRIPS provisions on patents, 106–25
  - exceptions that WTO members can allow to patent rights, 117–24
  - minimum period of protection to be accorded, 124
  - rights to be conferred on patent owners, 114–17
  - subject matter to be protected by patents, 107–14
  - waiver of members’ obligations, 31

- Performances and Phonograms Treaty,  
 WIPO, 41, 236
- performers. *See* related rights
- pharmaceutical exports, compulsory  
 licencing system. *See*  
 Paragraph 6 System
- pharmaceutical products. *See* TRIPS  
 and public health
- phonogram producers. *See* related  
 rights
- phonogram producers, related rights,  
 16, 18
- piracy. *See* counterfeiting, copying and  
 piracy
- plant new varieties  
 protection for, 113  
 review of Article 27.3(b), 113
- prior art, 23, 108, 109, 110
- provisional measures, 155–6  
 procedural requirements and  
 safeguards against abuse, 156  
 why and what type of, 155–6
- public goods, 3
- public health. *See* TRIPS and public  
 health
- related rights, 2, 39–40. *See also*  
 copyright and related rights
- broadcasting organizations, 17,  
 54, 56  
 national treatment, 18
- performers, 16, 54, 55, 56  
 national treatment, 18  
 protection of existing subject  
 matter, 26
- phonogram producers, 16, 26, 54,  
 55, 56  
 national treatment, 18  
 protection of existing subject  
 matter, 26
- purpose of protection of copyright  
 and related rights, 3, 40
- and Rome Convention, 12, 39, 41,  
 54, 56
- TRIPS provisions on related  
 rights, 54–7  
 copyright, 55–6  
 limitations and exceptions, 56  
 minimum term of protection, 56
- Rome Convention, 12, 34  
 broadcasting organizations, 17, 41  
 national treatment and MFN  
 treatment, 17  
 performers, 16, 41  
 phonogram producers, 16, 41  
 related rights. *See* related rights  
 and TRIPS Agreement, 16, 40–2
- security interests, 28  
 compulsory licensing, 122  
*ordre public*, 112
- special compulsory licencing system for  
 pharmaceutical exports. *See*  
 Paragraph 6 System
- spirits, protection for. *See* geographical  
 indications (GIs)
- Swedish International Development  
 Cooperation Agency, 234
- technology transfer and dissemination  
 current issues, 217, 235–6  
 Doha Declaration, 203  
 electronic commerce, 236  
 LDCs. *See* least-developed countries  
 (LDCs)
- objective of IP protection, 4,  
 14, 26  
 transitional arrangements, 26–7
- textile designs, 128–9, 147
- trade names, 63
- Trade Negotiations Committee, 10,  
 219, 220, 224, 226, 231
- Trade Policy Review Mechanism, 10, 33
- trade secrets. *See* undisclosed  
 information
- trademarks, 2, 58–84  
 conditions for registration as  
 a trademark, 64–70  
 priority, 64  
 publishing requirement, 64  
 reasons which may constitute  
 grounds for refusal of  
 registrations, 67  
 reasons which may not constitute  
 grounds for refusal of  
 registrations, 65–7

- reasons which must constitute grounds for refusal of registrations, 70
- EU trademarks, 72–4
- indefinite protection, 2, 84
- on the Internet, 236
- and Paris Convention, 58, 59, 60
  - relationship of TRIPS Agreement with pre-existing provisions, 60
- permissible exceptions to trademark rights, 81–4
  - no compulsory licensing permitted, 81–4
  - permitted exceptions, 81–3
- purposes of trademark protection, 4, 59
- reasons which may not constitute grounds for refusal of registrations, 65–7
  - actual use of trademark at time of registration, 67
  - failure to register in country of origin/independence of protection, 65
  - form of mark, if already registered in other member countries, 65–6
  - nature of goods/services identified by trademark, 66–7
- reasons which must constitute grounds for refusal of registrations, 70
  - geographical indications, 70, 97, 100
  - state emblems and official hallmarks, 37, 70
  - well-known marks, 70
- rights to be conferred on trademark owners, 71–80
  - general rights, 71
  - licensing and assignment of rights, 76
  - rights with respect to well-known trademarks, 74–6
  - trademark rights, 71–4
  - ‘twinning’ requirements, 77–80
- role of trademarks, 58–60
  - acquisition of trademark rights, 60
  - protection of service marks as well as trademarks for goods, 59
  - trademarks with respect to certain products, 59
- subject matter of trademark protection, 61–4
  - collective marks and certification marks, 63, 91, 94
  - distinctive signs, 61–3
  - trade names, 63
- trademark rights, 71–4
- TRIPS provisions on trademarks, 61–84
  - permissible exceptions to trademark rights, 81–4
  - rights to be conferred on trademark owners, 71–80
  - subject matter to be protected and conditions for registration, 61–70
  - term of protection, 2, 84
  - well-known trademarks, 70, 74–6
  - WIPO treaties on registration, 60
- traditional knowledge and folklore
  - CBD, 114, 229–31
  - current issues, 228–9
  - patents, 114, 228–9
  - WIPO Intergovernmental Committee on IP and Genetic Resources, Traditional Knowledge and Folklore, 229
- transfer of technology. *See* technology transfer and dissemination
- transitional arrangements and other matters, 13, 22–8
  - protection of existing subject matter, 25–6
    - additional requirements in respect of pre-existing works and phonograms, 26
    - application of rules, 25
    - security exceptions, 28
    - technical cooperation, 27–8
  - transfer of technology. *See* technology transfer and dissemination
- transition periods, 8, 22–5
  - acceding countries, 25

- transitional arrangements (cont.)  
   developed countries and  
     non-discrimination, 23  
   developing countries and  
     economies in transition, 23–4  
   LDCs, 24–5, 203, 233
- Treaty on Intellectual Property in  
 Respect of Integrated Circuits.  
*See* IPIC Treaty
- TRIPS Agreement  
   amending, 31  
   current TRIPS issues. *See* current  
     TRIPS issues  
   dispute prevention and settlement.  
     *See* dispute prevention and  
       settlement  
   enforcement. *See* enforcement  
   exceptions to national treatment and  
     MFN treatment, 18  
   general provisions. *See* general  
     provisions and basic principles  
     of TRIPS Agreement  
   historical and legal background to  
     TRIPS, 4–8, 17  
   and human rights. *See* human rights  
     and the TRIPS Agreement  
   intellectual property rights. *See*  
     intellectual property rights  
     (IPRs)  
   and other Conventions. *See* Berne  
     Convention; Convention on  
     Biological Diversity (CBD);  
     Paris Convention; Rome  
     Convention  
   overview of TRIPS provisions, 10–13  
   place of TRIPS in the WTO, 8–10  
     TRIPS Agreement administered  
     by TRIPS Council. *See* TRIPS  
     Council  
   and public health. *See* TRIPS  
     Agreement and public health  
   transitional arrangements. *See*  
     transitional arrangements and  
     other matters  
   TRIPS Agreement as integral part of  
     WTO Agreement, 8  
   waiver of members'  
     obligations, 31
- TRIPS Agreement and public health,  
 198–215  
   access to medicines, broader picture  
     of, 198, 216, 244–8  
   balancing incentives for research/  
     development and accessibility  
     to drugs, 198, 201  
   ‘Bolar’ provision, 118  
   compulsory licences for medicines/  
     pharmaceutical products, 121  
   emergency situations/public  
     health crises, 122, 201  
   export to countries lacking  
     domestic manufacturing  
     capacity, 122, 204, 208, 209  
   members free to decide grounds  
     on which licences granted, 201  
   Paragraph 6 System. *See*  
     Paragraph 6 System  
   right holder, adequate  
     remuneration for, 123, 204, 206  
   current TRIPS issues, 244–8  
   Doha Declaration. *See* Doha  
     Declaration on the TRIPS  
     Agreement and Public Health  
   undisclosed test and other data,  
     138–40  
   waiver decisions, 24, 31, 203, 204–5  
     amendment to the TRIPS  
     Agreement, 31
- TRIPS Council, 32–8  
   administering TRIPS Agreement, 8,  
     10, 32  
   consultations, 35  
   current TRIPS issues. *See* current  
     TRIPS issues  
   electronic commerce, 237  
   forum for further negotiation or  
     review, 35–6  
   GIs, 104  
   monitoring members’ compliance  
     with obligations, 167–8  
   non-violation and situation  
     complaints, scope and  
     modalities of, 172, 217  
   notifications, 33–4  
   public health, further work on,  
     203

- review of Paragraph 6 System's functioning, 214–15
  - review of national laws and regulations, 35, 167–8, 177
  - WTO and WIPO cooperation, 25, 36–8
- Understanding on Rules and Procedures Governing the Settlement of Disputes (DSU). *See* dispute prevention and settlement
- undisclosed information, 136–45
  - trade secrets and confidential information, 2, 137–8
  - information made subject to reasonable steps to keep it secret, 138
  - information that has commercial value because it is secret, 137
  - information that is secret, 137
  - length of protection, 2, 138
  - protecting trade secrets in enforcement proceedings, 152
- undisclosed test and other data, 138–40
- unfair competition, 2, 87, 96, 136, 140–2
  - anti-competitive practices control generally, 142–3
  - TRIPS provisions, 143–5
  - current TRIPS issues as to competition law, 240–1
  - free riding, 59, 96
- United Nations Conference on Trade and Development (UNCTAD), 234
- Uruguay Round. *See* General Agreement on Tariffs and Trade (GATT)
- US – *Gambling*, 177
- US – *Section 110(5) Copyright Act*, 41, 48, 50, 51–3, 178
  - summary of key Panel finding, 52–3
- US – *Section 211 Omnibus Appropriations Act*, 66, 68, 195
- US – *Upland Cotton*, 177
- utility models, 2, 132
- waiver of members' obligations under TRIPS Agreement, 31
  - and public health. *See* TRIPS and public health
- well-known trademarks, 70, 74–6
- wines and spirits, protection for. *See* geographical indications (GIs)
- World Health Organization (WHO), 28
  - cooperation with WIPO and WTO, 234
- World Intellectual Property Organization (WIPO), 12, 28, 105, 195
  - cooperation with WHO and WTO, 234
  - cooperation with WTO. *See* World Trade Organization (WTO)
- Copyright Treaty, 41, 236
- electronic commerce, 236
- Intergovernmental Committee on IP and Genetic Resources, Traditional Knowledge and Folklore, 229
- Performances and Phonograms Treaty, 41, 236
- trademarks. *See* trademarks
- World Trade Organization (WTO), 4
  - cooperation with UNCTAD, 234
  - cooperation with WHO and WIPO, 234
  - cooperation with WIPO, 36–8, 234
  - Joint Initiative on Technical Cooperation for Least-Developed Countries, 234
  - Council for Trade in Goods, 10
  - Council for Trade in Services, 10
  - Dispute Settlement Body (DSB), 10
  - forum for negotiations among members, 35–6
- GATT. *See* General Agreement on Tariffs and Trade (GATT)
- General Council, 10, 172
  - decision-making procedures, 29–32
- IP and competition policy current issues, 144
- Ministerial Conference, 10, 172

430

## INDEX

- World Trade Organization (cont.)  
 decision-making procedures,  
 29–32  
 non-discrimination as key  
 principle, 17  
 Trade Negotiations Committee, 10,  
 219, 220, 224, 226, 231  
 TRIPS. *See* TRIPS Agreement  
 WTO Agreement, 5, 8, 10, 28–32,  
 169
- amendment of multilateral trade  
 agreements, 31, 205  
 authoritative interpretations, 29  
 decision-making procedures, 29–32  
 scope of WTO Agreement, 28  
 Trade Policy Review Mechanism  
 8–9, 33  
 voting and consensus, 29  
 waiver of members' obligations, 31  
*WTO Analytical Index*, 196